Related Experiment Video
Updated: Nov 3, 2025
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung
R A El Shafie1, K Seidensaal1, F Bozorgmehr2
1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, Germany; Department of Radiology and Nuclear Medicines, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany.
Background:
The improved efficacy of tyrosine kinase inhibitors (TKI) mandates reappraisal of local therapy (LT) for brain metastases (BM) of oncogene-driven non-small-cell lung cancer (NSCLC).
Patients And Methods:
This study included all epidermal growth factor receptor-mutated (EGFR+, n = 108) and anaplastic lymphoma kinase-rearranged (ALK+, n = 33) TKI-naive NSCLC patients diagnosed with BM in the Thoraxklinik Heidelberg between 2009 and 2019. Eighty-seven patients (62%) received early LT, while 54 (38%) received delayed (n = 34; 24%) or no LT (n = 20; 14%). LT comprised stereotactic (SRT; n = 40; 34%) or whole-brain radiotherapy (WBRT; n = 77; 66%), while neurosurgical resection was carried out in 19 cases.
Results:
Median overall survival (OS) was 49.1 months for ALK+ and 19.5 months for EGFR+ patients (P = 0.001), with similar median intracranial progression-free survival (icPFS) (15.7 versus 14.0 months, respectively; P = 0.80). Despite the larger and more symptomatic BM (P < 0.001) of patients undergoing early LT, these experienced longer icPFS [hazard ratio (HR) 0.52; P = 0.024], but not OS (HR 1.63; P = 0.12), regardless of the radiotherapy technique (SRT versus WBRT) and number of lesions. High-risk oncogene variants, i.e. non-del19 EGFR mutations and 'short' EML4-ALK fusions (mainly variant 3, E6:A20), were associated with earlier intracranial progression (HR 2.97; P = 0.001). The longer icPFS with early LT was also evident in separate analyses of the EGFR+ and ALK+ subsets.
Conclusions:
Despite preferential use for cases with poor prognostic factors, early LT prolongs the icPFS, but not OS, in TKI-treated EGFR+/ALK+ NSCLC. Considering the lack of survival benefit, and the neurocognitive effects of WBRT, patients presenting with polytopic BM may benefit from delaying radiotherapy, or from radiosurgery of multiple or selected lesions. For SRT candidates, the improved tumor control with earlier radiotherapy should be weighed against the potential toxicity and the enhanced intracranial activity of newer TKI. High-risk EGFR/ALK variants are associated with earlier intracranial failure and identify patients who could benefit from more aggressive management.
Insights
Early local therapy for brain metastases in EGFR/ALK-positive non-small cell lung cancer improves intracranial progression-free survival but not overall survival. High-risk oncogene variants may benefit from more aggressive treatment strategies.
Area of Science:
- Oncology
- Neurology
- Radiotherapy
Background:
- Improved tyrosine kinase inhibitor (TKI) efficacy necessitates re-evaluating local therapy (LT) for brain metastases (BM) in oncogene-driven non-small cell lung cancer (NSCLC).
- EGFR-mutated (EGFR+) and ALK-rearranged (ALK+) NSCLC patients with BM are increasingly surviving longer, making optimal treatment of CNS disease critical.
Purpose of the Study:
- To assess the impact of early versus delayed/no local therapy on outcomes in TKI-naive EGFR+/ALK+ NSCLC patients with BM.
- To identify prognostic factors influencing intracranial progression and overall survival.
Main Methods:
- Retrospective analysis of 141 TKI-naive EGFR+ (n=108) and ALK+ (n=33) NSCLC patients with BM diagnosed between 2009-2019.
- Local therapy included stereotactic radiotherapy (SRT), whole-brain radiotherapy (WBRT), or neurosurgery. Patients were categorized into early LT (n=87) and delayed/no LT (n=54) groups.
- Comparison of overall survival (OS) and intracranial progression-free survival (icPFS) between groups, with subgroup analyses for EGFR+ and ALK+ patients and specific oncogene variants.
Main Results:
- Median OS was significantly longer for ALK+ (49.1 months) than EGFR+ (19.5 months) patients (P=0.001).
- Early LT was associated with longer icPFS (HR 0.52; P=0.024) but not OS (HR 1.63; P=0.12), irrespective of radiotherapy technique or lesion number.
- High-risk EGFR (non-del19) and ALK (variant 3) mutations were linked to earlier intracranial progression (HR 2.97; P=0.001).
Conclusions:
- Early LT improves icPFS but not OS in EGFR+/ALK+ NSCLC with BM, even when used preferentially for poor-prognosis cases.
- Given the lack of OS benefit and potential neurocognitive effects of WBRT, delaying radiotherapy or using selective SRT for polytopic BM might be considered.
- Patients with high-risk EGFR/ALK variants may benefit from more aggressive management strategies due to their propensity for earlier intracranial failure.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...